VA
MLTX icon

Vident Advisory’s MoonLake Immunotherapeutics MLTX Stock Holding History

Vident Advisory’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$339K Buy
18,208
+2,764
+18% +$45.8K ﹤0.01% 1442
2025
Q4 		$204K Buy
+15,444
New +$182K ﹤0.01% 1550

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vident Advisory's MLTX Position: Q1 2026 in Review

Vident Advisory increased its MoonLake Immunotherapeutics (MLTX) stake by 18% in Q1 2026, buying an estimated $45.8K and bringing the position to 18,208 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #1442.

Vident Advisory first reported a position in MLTX in Q4 2025 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Vident Advisory held 18,208 shares of MoonLake Immunotherapeutics worth $339K as of Q1 2026.
  • Vident Advisory bought 2,764 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $45.8K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1442 holding.
  • Vident Advisory first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.